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ABSTRACT 
Rabies is a major cause of human death in many developing countries. There is a worldwide shortage of human and equine rabies immune 
globulin. The WHO recommends combined administration of rabies vaccine and rabies immune globulin to patients after exposure.  The 
implementation of post exposure prophylaxis by vaccination and specific immunoglobulin therapy are largely hampered by its high cost. The 
equine rabies immunoglobulin is less expensive than human rabies immunoglobulin, and is used for rabies post-exposure prophylaxis in 
developing countries. 
Equine rabies immunoglobulin is a F(ab)2 with high specific activity, purity, and safety. Healthy horses are immunized with a rabies vaccine. 
Crude plasma is collected and immunoglobulin is converted into F(ab)2 fragments by pepsin digestion. The F(ab)2 fragments are  purified using 
caprylic acid precipitation followed by ultrafiltration. 
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INTRODUCTION 
RABIES 
Rabies is an acute viral disease of the central nervous system 
(CNS) that affects all warm-blooded animals including 
mammals.[1, 2, 3] It is an acute infectious encephalomyelitis, 
caused by a number of lyssaviruses including: rabies virus 
and Australian bat lyssavirus.[4] The rabies virus infects the 
central nervous system, ultimately causing disease in the 
brain and death. It is almost invariably fatal if post-exposure 
prophylaxis is not administered prior to the onset of severe 
symptoms. It is a zoonotic disease, spread most commonly 
by a bite from an infected animal. The disease is slow and 
progressive. The average incubation period of rabies is 1 to 2 
months, but may vary from one week to greater than one 
year, depending upon the site of dog bite, virulence of the 
virus, and the inoculation dose. The incubation period is 
short if the bite is on face, scalp, or neck because of the 
proximity to the brain. The prodormal phase comprises 
fever, nausea, vomiting, headache, fatigue, and other 
nonspecific symptoms. Some patients experience symptoms 
like pain, burning, prickling, or tingling sensations at the 
wound site [5].  
Post-bite treatment involves both post-bite vaccination 
using rabies tissue cultured antigen (active immunization) 
as well as administration of Antirabies immunoglobulin 
(passive immunization). Post-bite vaccination would result 
in development of immunoglobulins, but not earlier than 2-3 
weeks and therefore simultaneous administration of rabies 
immunoglobulin (antirabies serum) constitutes the best 
approach. Antirabies serum is injected locally in the biting 
wound area, immediately after dog-bite or preferably within 
eight days [6, 7, 8]. 
Epidemiology of rabies 
Rabies is endemic in most parts of the world except New 
Zealand and Antarctica and is the tenth leading cause of 
death due to infection in humans, predominantly affecting 
the poor people in the developing countries and remains a 
serious health problem. Even those countries declared 
rabies free like United Kingdom, Ireland, areas of 
Scandinavia, Japan, Australia, New Zealand, Singapore, 
Brunei, most parts of Malaysia, some islands of Indonesia, 
Papua New Guinea bear a risk due to the expanding 
prevalence of the disease.[9] 
About 65,000 people die due to rabies annually. This may be 
an underestimated figure because many cases go unreported 
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and misdiagnosed. Most cases are observed in Africa 
(24,000) and Asia (31,000); majority being in the developing 
countries; 99 % of all the cases are due to dog bites [6, 10]. 
Every 10 to 15 min. someone dies due to rabies, of which 
majority of the cases are children under 15 years of age. In 
children due to their short stature, dog-bites occur on the 
upper parts of the body, face, neck and hence are dangerous. 
More than 3.3 billion people from over 85 countries are at 
risk of rabies and prevalence of rabies is in more than 150 
countries and territories. Annually more than 15 million 
people receive post-exposure preventive treatment. Of 1.5 
million dog bite cases, 24,000 to 80,000 are from rabid dogs 
and require post exposure prophylaxis. [11] 
Transmission of rabies 
Rabies virus can cause disease in all warm blooded animals, 
especially mammals including humans. Rabies virus is 
predominantly neurotropic, killing the host after its growth 
in neurons. However before death, virus reaches salivary 
glands and is excreted in saliva. Mere licking of pre-existing 
scratch in skin is adequate for transmission of virus.  
Humans are infected primarily through a bite or scratch by 
an infected animal. Dogs are the main host in transmission of 
rabies, in 99% of all the human cases the virus is transmitted 
by dog bites. 
Human-to-human transmission by bite is the only 
theoretical possibility and has never been confirmed. 
Amongst the important reservoirs, dogs are the major cause 
of human deaths (99%) along with cats or wild animals 
(bats, monkeys & foxes). Transmissions of the disease to 
animals of great ecological interest like cattle and horses 
have been reported. 
As shown in Fig. No. 1 initially after entry into the host 
through the bite on the skin or mucous membrane, virus 
replicates in the striated muscle cells. It multiplies here for a 
week and then spreads to the peripheral nervous system 
(PNS) at the exposed neuromuscular junction sites and 
nerve endings at unmyelinated sites such as sensory and 
motor terminals.[12, 13] 
 
 
Fig. No. 1Transmission of rabies 
Source: www.microbiologyandimmunology, chapter twenty 
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ANTIRABIES SERUM 
Importance of antirabies serum 
 In the confirmed information about ‘health status’ of biting 
dog, each dog bite case is treated as exposure to rabies virus. 
In such case post-bite treatment involves both post-bite 
vaccination using rabies tissue cultured antigen (active 
immunization) as well as administration of Antirabies 
immunoglobulin (passive immunization). Post-bite 
vaccination would result in development of 
immunoglobulins, but not earlier than 2-3 weeks and 
therefore simultaneous administration of rabies 
immunoglobulin (antirabies serum) constitutes the best 
approach. Antirabies serum is injected locally in the biting 
wound area, immediately after dog-bite or preferably within 
eight days. [14] Rabies immunoglobulin not to administer in 
the same syringe or at the same injection site as rabies 
vaccine. [15, 16, 17, 18] 
Types of antirabies serum 
Two types of antirabies serum products are available for 
post exposure prophylaxis: 
Human Rabies Immunoglobulin (HRIG)  
Equine Rabies Immunoglobulin (ERIG)  
HRIG is prepared from the blood of human volunteers 
immunized with purified cell culture based rabies vaccine 
while ERIG is prepared from the blood of horses immunized 
with rabies vaccine. 
Human Rabies Immunoglobulin (HRIG) 
Human Rabies Immunoglobulin (HRIG) is a homologous 
preparation of refined, purified rabies immunoglobulin, i.e. 
immunoglobulins are human-proteins. To produce this 
immunoglobulin, human volunteers are immunized with 
purified cell culture based vaccines. HRIG is expensive (five 
times that of ERIG) and available in only limited quantities, 
because of involvement of human volunteers. Being 
homologous in nature, they do not cause any sensitization. 
The use of homologous immunoglobulins for human post-
exposure treatment virtually eliminates the risk of 
anaphylaxis and serum sickness associated with 
heterologous serum products. To avoid such reactions, 
human rabies immunoglobulin (HRIG) preparations have 
been developed and used for post exposure treatment in 
most industrialized countries. Also HRIG being of human 
origin are eliminated from the human body at much reduced 
rate. 
Equine rabies immunoglobulin (ERIG) becomes the 
immunoglobulin of choice, especially for the developing 
countries, where the animal bite cases are very much higher 
leading to greater requirement of immunoglobulins[6, 19, 20,21]. 
Equine Rabies Immunoglobulin (ERIG) 
Equine rabies immunoglobulin assumes great importance in 
treatment of post-bite cases with suspected exposure to 
rabies virus. ERIG can be made available in much larger 
quantities and also at much lesser cost. The heterogeneous 
nature can cause allergic reactions but the technological 
developments in processing of horse immunoglobulins have 
rendered them less allergic and more stable. Purification 
techniques can be used to reduce the risk of sensitization to 
ERIG. Their objective of purification is to maximize the 
specific activity and to minimize the allergenic substances in 
the product. These techniques are implemented with careful 
adherence to the recommendations of the WHO Expert 
Committee on Biological Standardization. The clinical safety 
of Equine Rabies Immunoglobulin is also well established. [9, 
22] In developing countries the use of highly purified horse 
immunoglobulin, are safer than the heterologous products of 
the previous generation. In the past few years, purified 
equine immunoglobulins have become available, and in 
recent studies, the incidence of serum sickness among 
recipients was reported to be as low as 1-6.2%. In India, 
manufacturers of Equine Rabies Immunoglobulin follow 
CPCSEA guidelines and cGMP norms. 
In developing countries, in general and India in particular, 
the need of RIG exceeds the production. In addition, the 
animal protection groups that are becoming more and more 
influential in developing countries, and they condemn 
animal rearing for serum production. [4, 9, 10]. 
PRODUCTION OF EQUINE RABIES 
IMMUNOGLOBULIN 
Hyper immune antibody preparation produced from animals 
serum have been used over the past century for the 
treatment of a variety of infectious agent and medical 
emergencies, including dioxin of toxicity, snake 
envenomation and spider bites. [13, 24] Traditionally equine 
IgG has been purified by pepsin digestion and Caprylic acid 
precipitation. [19]Equine rabies immunoglobulin (ERIG) has 
been produced using various immunogenic preparations, 
consisting usually of a combination of inactivated and fixed 
strains of rabies virus. The animals are given a series of 
injections of the vaccine in increasing quantities. All the 
injections are given subcutaneously into the lateral side of 
the neck. The general process of preparing equine rabies 
immunoglobulin as follows (Fig. No.2) 
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Fig. No. 2Antirabies serum manufacturing process 
Source: WHO Technical Report Series No. 1004, 2017, 252 
 
Immunization of horses 
Numerous  animal  species  have  been  used  on  various  
scales  in  antiserum production (horse, sheep, donkey, goat 
and rabbit) or for experimental purposes (camel, llama, dog 
and hen). However, the production of large volumes of 
antiserum from large animals such as equines is an 
advantage compared to the smaller species. The selection of 
the animal species should be based on several 
considerations, such as locally prevalent diseases, 
availability in the region, adaptation to the local 
environment, and cost of maintenance. The information in 
these guidelines refers mostly to horse-derived 
immunoglobulins. The horse is the animal of choice for 
commercial antivenom production. Horses are docile, thrive 
in most climates and yield a large volume of plasma. [25] 
Horses are purchased and kept isolated for a period of one 
month under observation and only healthy horses are taken 
for production. During this period, equines are immunized 
with tetanus toxoid. Primary immunization with Rabipur 
vaccines begins after the completion of quarantine period. 
[27]Horses are injected with gradually increasing doses of 
rabies antigen. Amount of antirabies antibodies in serum is 
determined using the ELISA test. After the required 
antirabies titer is obtained, the horses are taken for bleeding. 
The animals are bled from a jugular vein. Usually, 6-9 
months are required for immunization. 
Collection of hyper immune plasma 
Plasma  as  a  starting  material  is  preferred  to  serum  
largely  because red  blood  cells  can  be  returned  to  the  
animal,  thus  preventing  anaemia  and hypovolaemia in the 
donor animal and allowing more frequent bleeding. Some 
laboratories have found that using plasma enables higher 
recovery of antibodies per donation and it is less 
contaminated with haemoglobin (Hb) than serum. 
Separation of plasma from anticoagulated blood is much 
faster than separation of serum from clotted blood. Plasma 
for fractionation can be obtained either from the collection 
of whole blood or by the apheresis procedure. [25] 
From healthy immunized horses with respect to 
immunization and bleeding schedule withdraw 1.5% of body 
weight blood quantity from each animal in the sterilized 
glass bottles which contains anticoagulant solution, and kept 
the bottles in cold room at for settling of the cells at (5±3) °C 
overnight. The supernatant plasma is siphoned into another 
sterile bottle and stored in cold room till processed. Diethyl 
ether and phenol are added as preservative.  
Enzymatic digestion of plasma 
Antirabies prepared from the starting plasma pool to obtain 
one of the active substance F(ab)2 fragments. In general, 
fractionation procedures should not impair the neutralizing 
activity of antibodies; they should yield a product of 
acceptable physicochemical characteristics  and  purity  with  
a  low  content  of  protein  aggregates,  which  is non-
pyrogenic  and which  should  provide  good  recovery  of  
antibody  activity. [25] 
The method of pepsin digestion involves the digestion of 
horse plasma proteins by pepsin, leading to  the degradation 
of many non-IgG proteins, and to the cleavage of IgG into 
bivalent F(ab.)2 fragments by removal and  digestion  of  the  
Fc  fragment  into small  peptides.[26] 
The hyper immunized plasma is maintained at room 
temperature (22°C to 25°C) and diluted using WFI (Water 
for Injection). The pH was adjusted to 3.2± 0.2 with5M 
hydrochloric acid. At this pH and temperature, the 
proteolytic treatment with pepsin is carried out. The 0.1% 
w/v pepsin added for digestion under constant stirring for 3 
hours at 30-37°C for complete action of pepsin on IgG. The 
digestion was stopped by adding 10% v/v solution of 
sodium hydroxide and pH adjusted to 5.5± 0.3. 
 
Caprylic acid precipitation 
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Caprylic  acid  fractionation  allows  the  production  of  
antivenoms  of relatively  high  purity  and  with  a  low  
protein  aggregate  content,  because  the immunoglobulins  
are  not  precipitated  during  the  process.  The yield may 
reach up to 60–75% of the activity in the starting plasma, 
depending upon the particular procedure and/or the 
equipment used. The effectiveness and safety profiles of 
caprylic acid-fractionated antivenom immunoglobulins have 
been demonstrated in clinical trials. [28, 29, 30] 
The caprylic acid was added very carefully and slowly with 
constant stirring for 1 hour at 22° C to 25° C at variable 
strength to reach final concentration of 3% v/v and the 
mixture was centrifuged at 4400 rpm for 30 minute.  
Ultrafiltration 
The slurry is micro filtered and the filtrate thus obtained is 
subjected to ultrafiltration. This results in removal of 
ammonium sulphate and also in concentration of filtrate by a 
factor of ten. The ultra filtered antirabies serum thus 
obtained is described as one Lot. Based on the appropriate 
titer requirements in the finished product, lots are pooled 
together, diluted, and sterile filtered. 
During formulation after diafiltration steps the  addition  of  
salts  to  adjust  the  osmolality,  addition  of  preservatives,  
other excipients, if needed for protein stability, and the 
adjustment of pH7.0± 0.5 to improve stability and/or to 
reduce aggregate formation. Formulation at a pH higher than 
7.5 may not be recommended, since the stability of 
immunoglobulins and their fragments at alkaline pH may be 
poor, and the formation of aggregates may be favoured.[25] 
QUALITY CONTROL  
Potency of antirabies serum  
The different methods by which the antirabies antibodies in 
antirabies serum can be quantified are described as under: 
Virus neutralization test using mice 
This test is a WHO approved test for antirabies serum 
because it uses a large number of mice, it is not encouraged 
either by WHO or OIE. This test forms a part of 
Pharmacopoeial requirement for antirabies serum testing in 
countries like India. A constant dose of challenge virus (CVS) 
is mixed with a series of different dilutions of the antirabies 
serum under test and also with a reference serum standard 
which can be either a national or international standard 
antirabies serum. This antigen-antibody mixture is 
inoculated intracerebrally, in a set of mice (Swiss albino). 
The basis of the test is that after neutralization with the 
serum, the remaining free virus (if any) causes the death of 
the mice. [31, 32] 
Enzyme-linked Immunosorbent assay (ELISA) 
Enzyme-linked Immunosorbent assay is a diagnostic method 
used in detecting the presence of antibody or an antigen in a 
particular sample. The basic principle of an ELISA is to use 
an enzyme-tagged antibody to detect the antigen (Ag) 
antibody (Ab) reaction. The use of corresponding 
chromogenic substrate easily indicates antigen (Ag) 
antibody (Ab) reaction. An ELISA can be used to detect 
either the presence of antigens or antibodies in a sample, 
depending on design of the test. Commercial kits for testing 
of antirabies serum antibodies in human and dogs or cats 
are available. The ELISA test is acceptable as a prescribed 
test by OIE, provided that it has been validated and adopted 
on the OIE register. Virus neutralization tests may be used as 
confirmatory tests if desired. [33, 34] 
Protein content 
The protein concentration of sample determined UV-
spectrometrically at 550nm using standard Biuret method. 
The Biuret reaction, in which protein forms a complex with 
copper (Cu2+) in alkaline solution, has become the standard 
chemical test for total serum or plasma protein. This 
complex, which is dependent on the presence of peptide 
bonds, is blue-purple in color. The Biuret method is highly 
accurate for the range of total protein found in serum (1 to 
10 g/dl, 10 to 100 g/liter). [35, 36, 37] 
Phenol content 
Phenol content of samples determined UV-Vis 
spectrometrically at 450nm using 4-aminoantipyrine and 
dilute potassium ferricyanide in alkaline condition. [38] 
CONCLUSION 
Since rabies frequently occurring and the disease is life 
threatening, affects all warm blooded mammals, and its 
occurs is worldwide mostly in developing country.Post-bite 
treatment involves both vaccination using rabies tissue 
cultured antigen (active immunization) as well as 
administration of Antirabies immunoglobulin (passive 
immunization). Simultaneous administration of rabies 
immunoglobulin (antirabies serum) constitutes the best 
approach. Human rabies immunoglobulin is expensive five 
times that of equine rabies immunoglobulin and available in 
only limited quantities, because of involvement of human 
volunteers.  
Equine rabies immunoglobulin becomes the 
immunoglobulin of choice, especially for the developing 
countries, where the animal bite cases are very much higher 
leading to greater requirement of immunoglobulins. Equine 
rabies immunoglobulin can be made available in much larger 
quantities and also at much lesser cost. The technological 
developments in the processing of horse immunoglobulins, 
purification, and proteolytic treatment to immunoglobulins 
have rendered Equine rabies immunoglobulin less allergic 
and more stable. 
FUTURE CHALLENGES 
Rabies antiserum available in liquid form, it has shelf life 
only for two years and also requires storage condition 2°C to 
8°C so it is also expensive to maintain storage condition. So 
the future challenge is to develop Lyophilized Rabies 
antiserum to maximize stability, to maintain biological 
activity, safety, and marketability.  
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